CardioVascular and Interventional Radiology

, Volume 34, Issue 3, pp 493–501 | Cite as

Comparison of the Efficacy of the Embolic Agents Acrylamido Polyvinyl Alcohol Microspheres and Tris-Acryl Gelatin Microspheres for Uterine Artery Embolization for Leiomyomas: A Prospective Randomized Controlled Trial

  • Robert L. Worthington-KirschEmail author
  • Gary P. Siskin
  • Paul Hegener
  • Richard Chesnick
Clinical Investigation



To evaluate the efficacy of acrylamido polyvinyl alcohol microspheres (a-PVAM) as an embolic agent for uterine artery embolization (UAE) compared with Tris-acryl gelatin microspheres (TAGM).

Design, Setting, Participants

Prospective randomized double-blind noninferiority trial. Conducted at two sites both with regional UAE practices. Forty-six women with symptomatic leiomyomas.


UAE procedure was performed with either of the two embolic agents. Either 700–900-μm a-PVAM or 500–700-μm TAGM was used.

Main Outcome Measures

Changes in leiomyoma perfusion, overall uterine volume, and dominant leiomyomas volume measured by contrast-enhanced magnetic resonance imaging at 1 week, 3 months, and 6 months after UAE by a reader blinded to the embolic agent used. Changes in Uterine Fibroid Symptoms and Quality of Life questionnaire scores were measured at 3, 6, and 12 months after UAE.


Forty-six patients were randomized and treated under the study protocol (a-PVAM n = 22, TAGM n = 24). There were no procedure-related complications. Two patients were excluded from analysis (one technical failure of the procedure, one withdrawal from study). Successful (>90%) leiomyoma devascularization was observed in 81% of subjects at 1 week after UAE, 97% at 3 months after UAE, and 95% at 6 months after UAE. No significant differences were observed in 14 of 15 outcome measurements, consistent with noninferiority. TAGM was slightly superior to a-PVAM on one comparison (overall quality of life at 3 months after UAE).


Clinical practice Embolization Uterine artery embolization Uterine fibroid embolization Urogenital Uterine fibroid 



Unrestricted research grants from Terumo Interventional Systems USA (Somerset, NJ) and Biocompatibles UK (Farnham, Surrey, UK). Registered as NCT00361036 with

Conflict of interest

Drs. Hegener and Chesnick have no conflicts. Dr. Worthington-Kirsch has received an unrestricted educational grant from Terumo Interventional Systems USA and Biocompatibles for this study (no grant number, grant awarded in 2005). In the past (>3 years ago), Dr. Worthington-Kirsch received research support from Biosphere Medical and from Boston Scientific. Within the last year, Dr. Worthington-Kirsch has received honoraria for speaking to the U.S. sales forces of both Biocompatibles and Merit/Biosphere Medical. Dr. Siskin is a consultant to CeloNova and Boston Scientific.


  1. 1.
    Spies JB, Allison S, Flick P et al (2004) Polyvinyl alcohol particles and Tris-acryl gelatin microspheres for uterine artery embolization for leiomyomas: results of a randomized comparative study. J Vasc Interv Radiol 15:793–800PubMedGoogle Scholar
  2. 2.
    Spies JB, Allison S, Flick P et al (2005) Spherical polyvinyl alcohol versus Tris-acryl gelatin microspheres for uterine artery embolization for leiomyomas: results of a limited randomized comparative study. J Vasc Interv Radiol 16:1431–1437PubMedGoogle Scholar
  3. 3.
    Siskin GP, Beck A, Schuster M et al (2008) Leiomyoma infarction after uterine artery embolization: a prospective randomized study comparing Tris-acryl gelatin microspheres versus polyvinyl alcohol microspheres. J Vasc Interv Radiol 19:58–65PubMedCrossRefGoogle Scholar
  4. 4.
    Galvez JA, McCarthy S, Weinreb J et al (2008) Comparison of MRI outcomes of uterine artery embolization for uterine leiomyomas using Tris-acryl gelatin microspheres, polyvinyl alcohol spheres, and polyvinyl alcohol particles. J Comput Assist Tomogr 32:356–361PubMedCrossRefGoogle Scholar
  5. 5.
  6. 6.
    Pelage J, Guaou Guaou N, Jha R et al (2004) Long-term imaging outcome after embolization for uterine fibroid tumors. Radiology 230:803–809PubMedCrossRefGoogle Scholar
  7. 7.
    Spies JB (2009) What evidence should we demand before accepting a new embolic material for uterine artery embolization? J Vasc Interv Radiol 20:567–570PubMedCrossRefGoogle Scholar
  8. 8.
    Spies J, Coyne K, Guaou Guaou N et al (2002) The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 99:290–300PubMedCrossRefGoogle Scholar
  9. 9.
    Kroencke TJ, Scheurig C, Lampmann LE et al (2008) Acrylamido polyvinyl alcohol microspheres for uterine artery embolization: 12-month clinical and MR imaging results. J Vasc Interv Radiol 19:47–57PubMedCrossRefGoogle Scholar
  10. 10.
    Seron A, Pelage JP, Counord JL et al (2005) Rigidity and elasticity of Embosphere, Bead Block and Contour SE (abstract 89). Presented at Cardiovascular and Interventional Radiological Society of EuropeGoogle Scholar
  11. 11.
    Worthington-Kirsch RL (2005) Uterine artery embolization for fibroid disease. In: Van Sonnenberg E, McMullen W, Solbiati L (eds) Tumor ablation: principles and practice. Springer, New York, pp 414–417Google Scholar
  12. 12.
    Waltman AC, Courey AD, Athanasoulis C et al (1973) Technique for left gastric artery catheterization. Radiology 109:732PubMedGoogle Scholar
  13. 13.
    Cramer SF, Patel D (1990) The frequency of uterine leiomyomas. Am J Clin Pathol 94:435–438PubMedGoogle Scholar
  14. 14.
    Schwartz SM (2001) Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 44:316–326PubMedCrossRefGoogle Scholar
  15. 15.
    Namur J, Wassef M, Pelage JP et al (2005) Arterial location of three sizes of Embosphere and Bead Block in sheep uterus models (abstract 47.7.5). Presented at Cardiovascular and Interventional Radiological Society of EuropeGoogle Scholar
  16. 16.
    Stampfl S, Belleman N, Stampfl U et al (2009) Arterial distribution characteristics of Embozene particles, and comparison with other spherical embolic agents in the porcine acute embolization model. J Vasc Interv Radiol 20:1597–1607PubMedCrossRefGoogle Scholar
  17. 17.
    Sampson JA (1912) The blood supply of uterine myomata. Surg Gynecol Obstet 14:215–234Google Scholar
  18. 18.
    Spies JB, Benenati JF, Worthington-Kirsch RL (2001) Initial experience with use of Tris-acryl gelatin microspheres for uterine artery embolization for leiomyomata. J Vasc Interv Radiol 12:1059–1063PubMedCrossRefGoogle Scholar
  19. 19.
    Spies JB, Cooper JM, Worthington-Kirsch RL et al (2004) Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multicenter study. Am J Obstet Gynecol 191:22–31PubMedCrossRefGoogle Scholar
  20. 20.
    Chrisman HB, Dhand S, Rajeswaran S et al (2010) Prospective evaluation of the embolic agent bead block in the treatment of uterine leiomyomas with uterine artery embolization: a phase II study. J Vasc Interv Radiol 21:484–489PubMedCrossRefGoogle Scholar
  21. 21.
    Abramowitz SA, Israel GM, McCarthy SM et al (2009) Comparison of four embolic materials at uterine artery embolization by using postprocedural MR imaging enhancement. Radiology 250:482–487PubMedCrossRefGoogle Scholar
  22. 22.
    Spies JB, Myers ER, Worthington-Kirsch R et al (2005) The FIBROID Registry: symptoms and quality-of-life status 1 year after therapy. Obstet Gynecol 106:1309–1318PubMedCrossRefGoogle Scholar
  23. 23.
    Goodwin SC, Spies JB, Worthington-Kirsch R et al (2008) Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol 111:22–33PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010

Authors and Affiliations

  • Robert L. Worthington-Kirsch
    • 1
    Email author
  • Gary P. Siskin
    • 2
  • Paul Hegener
    • 2
  • Richard Chesnick
    • 3
  1. 1.Image Guided Surgery Associates, PC, c/o Peripheral Vascular Institute of PhiladelphiaPhiladelphiaUSA
  2. 2.Department of RadiologyAlbany Medical CollegeAlbanyUSA
  3. 3.Professional Diagnostic ImagingGlenmooreUSA

Personalised recommendations